Smith and Nephew receives NICE recommendation for Exogen

Smith and Nephew has welcomed news that the National Institute for Health and Clinical Excellence (NICE) has issued a draft recommendation for the Exogen ultrasound bone healing system.

The UK regulator has issued a favourable opinion on the use of the device to treat long bone fractures that have either shown a delay in healing or have been clinically assessed as non-union fractures.

A consultation period regarding its draft findings has now been opened, with members of the public to offer opinions on the potential approval of the product.

Exogen is manufactured by Bioventus and is characterised by its portable, lightweight design and ease of use.

John Everett, Smith and Nephew's vice-president of commercial operations for its biologics business, said the consultation "will allow patients, patient support groups and healthcare professionals to help define the appropriate use of Exogen so that these patients can get the best treatment while significant savings are made for the NHS".

Earlier this month, the company announced its second-quarter financial results, highlighting a two percent year-on-year increase in sales during the period.